Endo International PLC (NASDAQ:ENDP) (TSE:ENL) is scheduled to be issuing its quarterly earnings data before the market opens on Thursday, November 9th. Analysts expect the company to announce earnings of $0.66 per share for the quarter.

Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last announced its quarterly earnings data on Tuesday, August 8th. The company reported $0.93 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.19. The firm had revenue of $875.73 million for the quarter, compared to analyst estimates of $832.66 million. Endo International PLC had a negative net margin of 126.93% and a positive return on equity of 37.58%. The business’s quarterly revenue was down 4.9% compared to the same quarter last year. During the same period in the previous year, the company earned $0.86 earnings per share. On average, analysts expect Endo International PLC to post $4 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Shares of Endo International PLC (NASDAQ ENDP) opened at $5.93 on Wednesday. The firm has a market cap of $1,390.00, a price-to-earnings ratio of 1.28 and a beta of 0.53. The company has a current ratio of 1.02, a quick ratio of 0.80 and a debt-to-equity ratio of 10.20. Endo International PLC has a 1-year low of $5.77 and a 1-year high of $18.63.

ENDP has been the topic of a number of research analyst reports. Goldman Sachs Group, Inc. (The) initiated coverage on shares of Endo International PLC in a report on Thursday, September 28th. They set a “sell” rating and a $7.00 price objective on the stock. Piper Jaffray Companies reissued a “hold” rating and set a $9.00 price objective on shares of Endo International PLC in a report on Sunday, September 17th. Mizuho reissued a “buy” rating and set a $14.00 price objective (down from $19.00) on shares of Endo International PLC in a report on Tuesday, September 12th. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Endo International PLC in a report on Tuesday, August 8th. Finally, Zacks Investment Research lowered shares of Endo International PLC from a “buy” rating to a “hold” rating in a report on Thursday, October 12th. Four analysts have rated the stock with a sell rating, fifteen have given a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $12.64.

In other news, CEO Paul Campanelli acquired 6,500 shares of the firm’s stock in a transaction on Monday, August 14th. The stock was acquired at an average price of $7.71 per share, for a total transaction of $50,115.00. Following the completion of the transaction, the chief executive officer now owns 213,620 shares in the company, valued at approximately $1,647,010.20. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Terrance J. Coughlin acquired 20,000 shares of the firm’s stock in a transaction on Thursday, August 10th. The stock was purchased at an average price of $7.70 per share, with a total value of $154,000.00. Following the transaction, the chief operating officer now owns 181,369 shares of the company’s stock, valued at approximately $1,396,541.30. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 36,000 shares of company stock valued at $279,460. Insiders own 0.50% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/11/08/endo-international-plc-endp-scheduled-to-post-quarterly-earnings-on-thursday.html.

About Endo International PLC

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Earnings History for Endo International PLC (NASDAQ:ENDP)

Receive News & Stock Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related stocks with our FREE daily email newsletter.